Skip to main content

"Generation and Evaluation of ""Next-generation"" Antibody-Toxin-Conjugates for Cancer Therapy"

Objective

Therapeutic antibodies have transformed cancer therapy during the last decade, due to their high selectivity of targeting cancer cells in comparison to standard small molecule chemotherapy. Most recently, the coupling of cellular toxins to therapeutic antibodies has demonstrated an even greater efficacy in the therapy of cancer and the first, highly potent antibody drug conjugate (ADC), Adcetris®, was FDA approved in August 2011.
All ADCs currently in clinical development are generated by chemical conjugation of small molecule toxins to antibodies. This is an inefficient process, as site and ratio of toxin coupling cannot be controlled. In addition, the chemical conjugation involves chemical modification of potentially functional parts of the antibody. This can have negative effects on stability, specificity, CMC properties and the overall structure of the antibody. All this renders ADC manufacturing highly challenging, complicates regulatory procedures, and adds to development time and costs.
The SME consortium has complementary proprietary technologies and proposes to leverage this complementary expertise and know-how for defining novel processes of enzymatically conjugating small molecule toxins to antibodies that allow full control about toxin coupling site and ratio. Due to the high selectivity of enzymatic conjugation and physiologic conjugation conditions, it is expected that more homogeneous ADCs are generated with better CMC properties, higher potency, and at lower cost-of-goods in manufacturing. The consortium members believe that this represents a disruptive technology that will be highly competitive to traditional chemical conjugation, currently dominated by U.S.-based ADC technology companies Seattle Genetics and Immunogen. In addition to novel composition-of-matter IP, important novel know-how for ADC development will be created. Most importantly, better quality and potency of these “next-generation” ADCs will eventually benefit cancer patients.

Call for proposal

FP7-SME-2013
See other projects for this call

Coordinator

NBE-THERAPEUTICS AG
Address
Hochbergerstrasse 60c Technologie Park Basel
4057 Basel
Switzerland

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Ulf Grawunder (Dr.)
EU contribution
€ 422 380

Participants (11)

ERA BIOTECH

Participation ended

Spain
EU contribution
€ 171 758,16
Address
Calle Baldiri Reixac 15-21
08028 Barcelona

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Miriam Bastida (Dr.)
TUBE PHARMACEUTICALS GMBH
Austria
EU contribution
€ 276 615
Address
Leberstrasse 20
1110 Wien

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Wolfgang Richter (Dr.)
EVITRIA AG
Switzerland
EU contribution
€ 14 540
Address
Wagistrasse 25-27
8952 Schieren

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Markus Hildinger (Dr.)
PROTAGEN PROTEIN SERVICES GMBH
Germany
EU contribution
€ 16 040
Address
Otto Hahn Strasse 15
44227 Dortmund

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Martin Blueggel (Dr.)
CHARLES RIVER DISCOVERY RESEARCH SERVICES GERMANY GMBH
Germany
EU contribution
€ 12 760
Address
Am Flughafen 12-14
79108 Freiburg

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Silvia Naus (Dr.)
Westfälische Wilhelms-Universität Münster

Participation ended

Germany
Address
Schlossplatz 2
48149 Muenster

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Katharina Steinberg (Dr.)
JPT PEPTIDE TECHNOLOGIES GMBH
Germany
EU contribution
€ 8 800
Address
Volmerstrasse 5 Utz
12489 Berlin

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Karsten Schnatbaum (Dr.)
BIOMEDAL SL
Spain
EU contribution
€ 8 800
Address
Avenida Americo Vespucio 5, Bloque 4, Planta 1a, Modulo 12, Parque Cientifico Y Tecnologico Cartuja 39
41092 Sevilla

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Angel Cebolla (Dr.)
TBD-BIODISCOVERY OU
Estonia
EU contribution
€ 7 590
Address
Tiigi 61b
50410 Tartu

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Olga Tsubrik (Dr.)
INNO TUNE BVBA
Belgium
EU contribution
€ 9 040
Address
Voorhoutkaai 20
9000 Gent

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Lieven De Smedt (Mr.)
ZERA INTEIN PROTEIN SOLUTIONS SL
Spain
EU contribution
€ 112 676,84
Address
Cavallers 50
Barcelona

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Miriam Bastida (Dr.)